Results 31 to 40 of about 53,609 (266)

Expression of c-erbB-2 protein in papillary thyroid carcinomas [PDF]

British Journal of Cancer, 1992
c-erbB-2 protein expression was investigated immunohistochemically in frozen thyroid tissue specimens from 42 patients using a polyclonal sheep antibody. c-erbB-2 immunoreactivity was detected in 12 out of 17 papillary carcinomas, while no c-erbB-2 protein immunostaining was seen in cases of follicular adenoma (five cases), follicular carcinoma (five ...
D R, Haugen, L A, Akslen, J E, Varhaug, J R, Lillehaug   +3 more
openaire   +2 more sources

P-cadherin overexpression Is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation [PDF]

, 2005
Purpose: P-cadherin overexpressionhas been reported in breast carcinomas,where itwas associated with proliferative high-grade histological tumors. This study aimed to analyze P-cadherin expression in invasive breast cancer and to correlate it with tumor ...
Albergaria, André, Jerónimo, Carmen, Milanezi, Fernanda, Oliveira, J. T., Paredes, Joana, Schmitt, Fernando C.   +5 more
core   +1 more source

Tumor markers in breast cancer - European Group on Tumor Markers recommendations [PDF]

, 2005
Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer.
Abraha RS, Andreasen PA, Arie van Dalen, ASCO Expert Panel, Barak V, Barnes DM, Baselga J, Bast RC, Benraad TH, Bieglmayer C, Blamey RW, Bonadonna G, Chan DW, Chebil G, Chu KC, Colditz G, Conneely OM, De Koning H, Devine PL, Dixon AR, Dnistrian AM, Dnistrian AM, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Early Breast Cancer Trialist's, Early Breast Cancer Trialists Collaborative Group, Early Breast Cancer Trialists Collaborative Group, Easton DF, Ebeling FC, Ebeling FG, Eifel P, Einarsson R, Ekbom A, Elledge RM, Fisher B, Fitzgibbons PL, Gion M, Gion M, Guadagni F, Gyö, Harries M, Harvey JM, Helena Goike, Holli K, Holli K, Iwase H, Jager W, Jensen EV, Kamel EM, Konecny G, Kurebayashi J, Lamerz R, Leake R, Leers M, Leers MP, Leers MP, Legha SS, Leyland-Jones B, Look MP, Loomer L, Loprinzi CL, Madigan MP, Marius Nap, Massimo Gion, McCarty, McLaughlin R, Merimsky O, Michael J. Duffy, Mohsin SK, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Morrow M, Nakata B, Newcomb P, Nicolini A, Nicolini A, Nicolini A, O'Hanlon DM, Paik S, Palazzo S, Parker SL, Parkin DN, Pecking AP, Pertschuk LP, Pertschuk LP, Petra Stieber, Piccart MJ, Price MR, Rafael Molina, Robertson JFR, Robertson JFR, Rogers CE, Roland Einarsson, Rolf Lamerz, Romer M, Rosselli del Turco M, Safi F, Schapira DV, Schapira DV, Sjostrom J, Slamon D, Soletormos G, Soletormos G, Soletormos G, Soletormos G, Stieber P, Sturgeon CM, Sweep CGJ, Tabar L, The GIVIO, The GIVIO, Theriault RL, Thorpe SM, Tomlinson IP, Tondini C, Van Dalen A, Van Dalen A, van Dalen A, van Dalen A, Van Dalen A, van Dalen A, Veronesi U, Vivian Barak, Vizcarra E, Vyzula R, Weihua Z, Williams MR, Yamauchi H, Zucchelli GC   +136 more
core   +1 more source

Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer

Cell Death and Disease, 2022
Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2.
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo   +18 more
doaj   +1 more source

Detection of c-erbB-2 mRNAs Using Dig-Labelled Oligonucleotide Probe with in situ Hybridisation in Human Breast Carcinoma: Comparison with Immunohistochemical Results

Analytical Cellular Pathology, 1998
Amplification and overexpression of the c-erbB-2 oncogene are of prognostic significance in human breast cancer. Overexpression of c-erbB-2 is the result of gene amplification.
Melek Öztürk, Sema Bolkent, Selma Yilmazer, Gültekin Kaner, Hilal Ünal   +4 more
doaj   +1 more source

Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients

BMC Cancer, 2006
Background The inactivation of the tumour suppressor gene and activation of the proto-oncogene are the key steps in the development of the human cancer. The p53 and c-erbB-2 are the best examples of it.
Singh Usha, Garbyal RS, Tewari Mallika, Chaube Amita, Shukla Hari S   +4 more
doaj   +1 more source

EGF and TGF-β1 effects on thyroid function [PDF]

, 2011
Normal epithelial thyroid cells in culture are inhibited by TGF-β1. Instead, transformed thyroid cell lines are frequently resistant to its growth inhibitory effect. Loss of TGF-β responsiveness could be due to a reduced expression of TGF-β receptors, as
Gabriella Mincione, Maria Carmela Di Marcantonio, Chiara Tarantelli, D'INZEO, SONIA, NICOLUSSI, Arianna, NARDI, Francesco, Caterina Francesca Donini, COPPA, Anna   +7 more
core   +2 more sources

Membranous Levels of C-Erbb-2 Oncoprotein in Gastric Cancer: Their Relationship with Clinicopathological Parameters and Their Prognostic Significance

The International Journal of Biological Markers, 2004
Background The protein encoded by the c-erbB-2 gene is a membrane receptor expressed in a variety of solid human cancers and directly related to poor prognosis.
F.J. Vizoso, M.D. Corte, A. Alvarez, I. García, J.M. del Casar, M. Bongera, L.O. Gonzílez, J.L. García-Muñiz, M.T. Allende   +8 more
doaj   +1 more source

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. [PDF]

PLoS ONE, 2015
EGFR mutation-induced drug resistance has become a major threat to the treatment of non-small-cell lung carcinoma. Essentially, the resistance mechanism involves modifications of the intracellular signaling pathways.
Debby D Wang, Lichun Ma, Maria P Wong, Victor H F Lee, Hong Yan   +4 more
doaj   +1 more source

Epidermal Growth Factor Receptor and c-erbB-2 Contents in Unresectable (UICC R1 or R2) Gastric Cancer

The International Journal of Biological Markers, 2003
Background Epidermal growth factor receptor (EGFR) and c-erbB-2 are membrane receptors expressed in a variety of solid human cancers and directly correlated with poor prognosis.
I. García, J.M. Del Casar, M.D. Corte, M.T. Allende, J.L. García-Muñiz, F. Vizoso   +5 more
doaj   +1 more source